The share price of Shattuck Labs, Inc. (NASDAQ: STTK) saw a little gain on Thursday during the extended trading session. STTK shares decreased 9.26% to $4.16 at the close of the regular session, but then increased 5.64% to $4.40 in the after-market trading. Even though there were no noteworthy fresh events, the market's better attitude seemed to be the driving force behind the stock price's recent surge.
- Updated Clinical Trial Data
- Encouraging Results And Future Plans
Updated Clinical Trial Data
Shattuck Labs (STTK) last week announced a preliminary result from the Phase 1B dose expansion clinical study of SL-172154 with azacitidine for frontline HR-MDS and TP53-mutant AML patients. On June 14, 2024, Shattuck gave a poster session presentation of his findings at the European Hematology Association (EHA) 2024 Congress. The information emphasized SL-172154's distinct mode of action and confirmed its status as a top CD47 inhibitor in hematologic malignancies.
Encouraging Results And Future Plans
The latest data reveal an improvement in the complete remission rate since the previous update in December, with additional patients in both cohorts showing continued progress. Due to these promising results, Shattuck Labs is concentrating its efforts on HR-MDS and TP53-mutated AML, areas with significant unmet needs, minimal competition, and potential for expedited approval pathways.
The accumulating evidence highlights the therapeutic potential and manageable safety profile of SL-172154 for patients with previously untreated HR-MDS and TP53-mutated AML. Clinical evidence suggests a pharmacodynamic effect of CD40 activation in the peripheral blood and a developing correlation between clinical remission and CD40-mediated cytokine induction.
Patients treated by Shattuck Labs represent a high-risk group with historically short durations of complete remission and overall survival when treated with azacitidine alone. The median overall survival and duration of remission have not yet been reached.
Shattuck Labs plans to share additional data on treatment durability later this year and is actively enrolling patients in the randomized, controlled expansion cohort for frontline HR-MDS. The company anticipates regulatory discussions later this year to define the registration strategy for SL-172154.
周四在延长交易时段中,Shattuck Labs公司 (纳斯达克: STTK) 股票价格有所上涨。在常规交易结束时,STTK股票价格跌了9.26%,至4.16美元,但在盘后交易中涨了5.64%,至4.40美元。尽管没有什么值得注意的新鲜事,但市场的良好态度似乎是股票价格最近上涨的推动力。
更新的临床试验数据
Shattuck Labs (STTK) 上周公布了SL-172154与前线高风险肿瘤综合征(HR-MDS)和TP53突变AML患者使用阿扎胞苷的1B剂量扩大临床研究的初步结果。2024年6月14日,Shattuck在欧洲血液学协会(EHA)2024年会议上展示了他的研究成果。该信息强调了SL-172154的独特作用方式,并确认其作为血液学恶性肿瘤领域顶尖的CD47抑制剂的地位。
鼓舞人心的结果和未来计划
最新数据显示,与去年12月的更新相比,完全缓解率有所提高,两个队列中的患者显示出持续的进展。由于这些有希望的结果,Shattuck Labs将其力量集中在HR-MDS和TP53突变AML等零售销售点,这些领域有着巨大的未满足需求,很少有竞争,具有加速批准途径的潜力。
积累的证据突出了SL-172154对先前未治疗的HR-MDS和TP53突变AML患者的治疗潜力和可管理的安全性。临床证据表明,CD40激活在外周血液中产生药效作用,并在CD40介导的细胞因子诱导和临床缓解之间产生了关联。
由Shattuck Labs治疗的患者代表了一个高风险股票群体,当单独使用阿扎胞苷治疗时,缓解期的中位数和总生存期尚未达到。
Shattuck Labs计划在今年晚些时候共享更多关于治疗持久性的数据,并积极招募前线HR-MDS的随机对照扩展队列中的患者。该公司预计在今年晚些时候进行监管讨论,以定义SL-172154的注册策略。